CV Sciences Terminates Material Definitive Agreement
Ticker: CVSI · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1510964
| Field | Detail |
|---|---|
| Company | Cv Sciences, Inc. (CVSI) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
Related Tickers: CVSI
TL;DR
CV Sciences terminated a big deal on Feb 5th. Details TBD.
AI Summary
CV Sciences, Inc. filed an 8-K on February 11, 2025, to report the termination of a material definitive agreement that occurred on February 5, 2025. The filing does not provide specific details about the agreement or the counterparty involved.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's business relationships and financial commitments.
Key Players & Entities
- CV Sciences, Inc. (company) — Registrant
- February 5, 2025 (date) — Date of earliest event reported
- February 11, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What was the nature of the material definitive agreement that was terminated?
The filing does not specify the nature of the material definitive agreement that was terminated.
Who was the counterparty to the terminated material definitive agreement?
The filing does not disclose the identity of the other party to the terminated agreement.
What is the effective date of the termination of the material definitive agreement?
The material definitive agreement was terminated on February 5, 2025.
What are the potential financial or operational impacts of this termination on CV Sciences, Inc.?
The filing does not provide details on the potential impacts of the termination.
Will CV Sciences, Inc. be filing any amendments or further details regarding this termination?
The filing does not explicitly state whether further details will be provided, but an 8-K typically reports significant events.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2025-02-11 17:04:30
Filing Documents
- cvsi-20250205.htm (8-K) — 43KB
- 0000950170-25-018048.txt ( ) — 141KB
- cvsi-20250205.xsd (EX-101.SCH) — 22KB
- cvsi-20250205_htm.xml (XML) — 4KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement On November 21, 2024, CV Sciences, Inc. (the "Company") announced that it entered into a definitive Stock Purchase Agreement (the "Purchase Agreement") by and among the Company, Extract Labs Inc., a Colorado corporation ("Extract Labs"), Craig Henderson ("Henderson") and Higher Love Wellness Company, LLC ("Higher Love" and together with Extract Labs and Henderson, the "Sellers") to purchase all of the outstanding shares of Extract Labs from the Sellers. Disclosure of the terms and conditions of the Purchase Agreement that are material to the Company was included in Item 1.01 of the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 21, 2024, and is incorporated herein by reference. On February 5, 2025, the Company received an electronic mail message from Henderson indicating that the Sellers were unable to move forward with the closing under the Purchase Agreement due to the alleged failure to receive a bank consent and were apparently terminating the Purchase Agreement. The Company disputes the Sellers' right to terminate the Purchase Agreement and the Company reserves all of its rights under the Purchase Agreement. The Company is presently evaluating its options related to the Sellers' purported termination of the Purchase Agreement. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CV SCIENCES, INC. Date: February 11, 2025 By: /s/ Joseph Dowling Joseph Dowling Chief Executive Officer 2